Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

We are at a turning point in the fight against Alzheimer’s disease with the emergence of disease-modifying therapies for ...

Blood biomarkers at disease onset may help predict relapse-associated worsening and progression independent of relapse ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

A common immunotherapy approach helped stave off disease progression in patients with a form of anal cancer that is caused by ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

In a fully adjusted model based on pooled data, the risk of a 40% or greater eGFR decline or end-stage kidney disease (ESKD) was significantly increased 55% per doubling of annual average baseline ...

Peripheral artery disease is a growing problem among the hemodialysis population, and anemia parameters might influence this risk.

Relay Therapeutics said on Monday interim data from an early-stage study of its experimental combination treatment for breast cancer showed it meaningfully extended the time patients lived without ...